S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Halozyme Therapeutics, Inc.

HALO XNAS
$103.12 +16.68 (+19.45%) ▲ 15-min delayed
Open
$90.00
High
$103.30
Low
$90.00
Volume
7.83M
Market Cap
$10.17B

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 423 Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $376.71M $150.05M $1.27
FY 2025 $1.40B $316.89M $2.64
Q3 2025 $354.26M $175.22M $1.49
Q2 2025 $325.72M $165.16M $1.36

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026
Calendar →

Related Market News

No specific coverage for HALO yet. Check out our latest market news or earnings calendar.

Get HALO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Halozyme Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.